Introduction
How GLP-1 RAs may reduce intracranial pressure and pain
The disease biology driving IIH
GLP-1 RAs in IIH
Emerging evidence in migraine
Real-world observations
References
Further reading
GLP-1 receptor agonists are emerging as promising investigational therapies for idiopathic intracranial hypertension, with evidence suggesting reductions in intracranial pressure, headache burden, papilledema, and visual complications. Their potential role in primary migraine remains far less certain and requires dedicated randomized clinical trials.
Image Credit: PeopleImages / Shutterstock.com
Introduction
Migraine and idiopathic intracranial hypertension (IIH) are distinct neurological conditions, although headache is a major feature of both, and IIH headache frequently has a migraine-like phenotype.1,5,6 The frequent coexistence of obesity and IIH, together with the metabolic actions of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), has led researchers to investigate whether GLP-1 RAs may provide therapeutic benefits beyond weight loss.1,3,4
This article explores the emerging off-label therapeutic potential of GLP-1 RAs in migraine and IIH, highlighting their mechanisms, current clinical evidence, benefits, limitations, and future research directions for headache and intracranial pressure management. However, the clinical evidence is currently considerably stronger for IIH than for primary migraine.1,2,3,4,6
How GLP-1 RAs may reduce intracranial pressure and pain
GLP-1 receptors are expressed in the CNS, including the choroid plexus, providing a potential pathway through which GLP-1 signaling could influence CSF dynamics. Preclinical studies have reported reductions in CSF secretion or intracranial pressure following GLP-1 receptor agonism, supporting a possible choroid plexus mechanism, although the mechanism responsible for ICP lowering in humans remains unestablished. Nevertheless, a small randomized trial of exenatide in IIH demonstrated a rapid reduction in intracranial pressure within hours, before meaningful weight loss could occur, supporting the possibility of a weight-independent pharmacological effect.1,3
In addition to the impact of GLP-1 RAs on metabolism and potentially CSF dynamics, experimental literature has described neuroprotective and anti-inflammatory actions of GLP-1 signaling.1,3 These properties provide possible mechanistic links to headache biology, but they have not yet established GLP-1 RAs as a treatment for primary migraine.1,6 However, the precise mechanisms underlying these effects and their clinical relevance continue to be investigated.
GLP-1 drug could offer relief to migraine sufferers
The disease biology driving IIH
IIH is a neurological disorder characterized by elevated intracranial pressure in the absence of an identifiable secondary cause.5 IIH typically affects women of reproductive age with obesity and manifests as a chronic headache, papilledema, pulsatile tinnitus, transient visual disturbances, and, in severe cases, progressive visual impairment. If left untreated, IIH can also result in irreversible vision loss.5,6
Although the exact pathophysiology of IIH remains unclear, obesity is the most consistently recognized modifiable risk factor and is closely linked to metabolic and hormonal disturbances that may influence intracranial pressure regulation. Proposed mechanisms include altered CSF dynamics, abnormalities in intracranial venous pressure or drainage, and metabolic, hormonal, and neurovascular factors; their relative contributions remain incompletely understood.3,5
Current management focuses on weight reduction and therapies such as acetazolamide, with surgical or procedural approaches reserved for cases where vision is threatened or the disease is refractory.1,5 GLP-1 RAs have gained attention for treating this condition, as these agents may target both weight-dependent and weight-independent mechanisms. Specifically, in addition to promoting sustained weight loss, GLP-1 RAs may influence choroid plexus CSF transport, while the rapid ICP reduction observed with exenatide provides clinical evidence that at least some effects may occur independently of weight loss.1,3
GLP-1 RAs in IIH
Clinical data suggest that GLP-1 RAs are associated with reductions in headache burden and papilledema and with a lower risk of visual deterioration in some studies.1,2,3,4 For example, one meta-analysis reported significantly fewer monthly headache days with GLP-1 RAs, whereas the small randomized exenatide trial demonstrated rapid ICP lowering but did not establish statistically significant superiority for all headache or visual outcomes.1,3 In one pooled analysis, GLP-1 or dual GIP/GLP-1 therapy was associated with relative risks of 0.25 for papilledema and 0.41 for visual disturbances or blindness compared with standard care.3 In addition to symptomatic improvement, several observational and registry-based analyses have associated GLP-1 RA use with reduced treatment escalation, acetazolamide use, and CSF-shunting or other surgical interventions; these associations should not yet be interpreted as definitive causal effects.1,2,4
Overall, GLP-1 RAs have a favorable safety profile, with the most commonly reported adverse events being mild gastrointestinal side effects. However, currently available data include only limited randomized evidence alongside prospective and retrospective observational studies, some of which use large administrative or registry datasets that may overlap.1,2,3,4 Although one recent meta-analysis included 13,257 participants, much of this numerical strength came from retrospective data rather than independent randomized trials.2 This potential overlap, together with differences in drugs, outcome definitions, concomitant treatment, and follow-up, limits the certainty of pooled estimates. Larger and better-designed randomized clinical trials are needed to confirm the long-term efficacy, safety, and role of GLP-1 RAs in the routine management of IIH.1,2,3,4
Image Credit: vector next / Shutterstock.com
Emerging evidence in migraine
Research on GLP-1 RAs for the treatment of primary migraine remains substantially less developed than the evidence in IIH. Although GLP-1 signaling has neuroprotective, metabolic, and potentially anti-inflammatory effects that provide hypotheses for effects on pain pathways, evidence that these mechanisms translate into clinically meaningful migraine prevention is currently insufficient. Likewise, the reduction in CSF production or intracranial pressure proposed for IIH should not be assumed to benefit primary migraine, for which raised intracranial pressure is not a defining mechanism.1,6
Reports of reduced headache frequency during GLP-1 RA treatment largely arise from populations with IIH, in whom headache improvement may reflect reductions in ICP, weight loss, other pharmacological effects, or a combination of these mechanisms.1,3,4 Because IIH headache itself frequently resembles migraine, improvement in migraine-like headache in IIH does not demonstrate efficacy against primary migraine as a separate disorder.1,5,6 These findings therefore cannot be directly generalized to patients with migraine without IIH. Dedicated randomized controlled trials in well-characterized primary migraine populations are needed to determine whether GLP-1 RAs have an independent antimigraine effect, which patients might benefit, and whether any benefit is related to weight loss or direct neural mechanisms.1,6
Real-world observations
Several observational trials, registry-based analyses, and early clinical studies have shown improvement in headache frequency, papilledema, visual symptoms, and total disease control. Likewise, other studies have described reduced reliance on acetazolamide and a lower likelihood of requiring surgical interventions, suggesting that GLP-1 RAs may offer meaningful benefits when used alongside standard management.1,2,3,4 However, the magnitude and consistency of benefit vary according to the outcome and study design; short-term clinical studies have not uniformly demonstrated additional visual-field or visual-acuity improvement despite favorable associations in larger retrospective datasets.1,3
Individual treatment response remains insufficiently characterized, and current observational datasets cannot reliably identify distinct responder and non-responder subgroups. Differences in disease severity, baseline obesity, GLP-1 agent, concomitant IIH therapy, and weight loss may all contribute to heterogeneity in observed outcomes.1,3
Most available real-world evidence has been obtained from observational studies, which are vulnerable to residual confounding, selection bias, outcome misclassification, and, in some analyses, potential overlap between large electronic health record cohorts. Consequently, larger and better-designed randomized controlled trials are needed before GLP-1 RAs can be routinely recommended for IIH management. Mechanistic studies are also needed to clarify patient selection, optimize treatment strategies, and establish the precise role of these agents in headache disorders.1,2,3,4
References
- Ognard, J., Alipour Khabir, S., Ghozy, S., et al. (2025). Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: a systematic review. The Journal of Headache and Pain 26(1). DOI: 10.1186/s10194-025-02148-3. https://link.springer.com/article/10.1186/s10194-025-02148-3
- Ahmed, W., Gandhi, O. H., Yu, N., et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis. Journal of the Neurological Sciences 480, 125711. DOI: 10.1016/j.jns.2025.125711. https://www.sciencedirect.com/science/article/pii/S0022510X25023330
- Stefanou, M. I., Chatziralli, I., Lambadiari, V., et al. (2025). Efficacy and Safety of GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis. European Journal of Neurology 32(9). DOI: 10.1111/ene.70358. https://onlinelibrary.wiley.com/doi/10.1111/ene.70358
- Ahmad, J., Hamdy, A. M., Elfakharany, B., et al. (2025). The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders 18. DOI: 10.1177/17562864251378845. https://journals.sagepub.com/doi/10.1177/17562864251378845
- Toshniwal, S. S., Kinkar, J., Chadha, Y., et al. (2024). Navigating the enigma: a comprehensive review of idiopathic intracranial hypertension. Cureus 16(3). DOI: 10.7759/cureus.56256. https://www.cureus.com/articles/237853-navigating-the-enigma-a-comprehensive-review-of-idiopathic-intracranial-hypertension#!/
- Hariga, C., Bordeanu-Diaconescu, E., Cretu, A., et al. (2026). Integrative Migraine Therapy: From Current Concepts to Future Directions - A Plastic Surgeon’s Perspective. Medicina 62(1). DOI: 10.3390/medicina62010050. https://www.mdpi.com/1648-9144/62/1/50
Further Reading
Last Updated: Aug 17, 2026